Do you want to read an article? Please log in or register.
PALLAS: Predictors of early palbociclib discontinuation in patients with early breast cancer
Breast Cancer
SABCS 2025
Related content
Breast Cancer
Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer
Ann Oncol
Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025
doi: 10.1016/j.annonc.2025.09.007
Breast Cancer
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies
Int J Cancer
García-Saenz JA, Spera G, Pollán M, Bermejo B, Ruiz-Borrego M, Chan A, Martín M, Guerrero-Zotano Á, Calvo L, Rodríguez-Lescure Á, Marín M, Chap L, Crown J, Pienkowski T, Bee V, Casas M, Polonio Ó, Bezares S, Slamon D
doi: 10.1002/ijc.35432
ESMO 2025
Breast Cancer
monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer
SABCS 2025
Breast Cancer
DESTINY-Breast11: T-DXd followed by THP shows manageable and more favorable safety profile versus ddAC–THP in patients with high-risk HER2-positive early breast cancer
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
Breast Cancer
Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial
Eur J Cancer
Dauccia C, Alice Franzoi M, Martel S, Agbor-Tarh D, Fielding S, Piccart M, Bines J, Loibl S, Di Cosimo S, Vaz-Luis I, Di Meglio A, Del Mastro L, Gombos A, Desmedt C, Jerusalem G, Reaby L, Pienkowski T, Lambertini M, Agostinetto E, Azambuja E, APHINITY Steering Committee and Investigators
doi: 10.1016/j.ejca.2025.115489
Breast Cancer
Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group
Lancet Oncol
Jensen MB, Torpe E, Teunissen Z, Taarnhøj G, Brix E, Knoop A, Yammeni S, Donskov F, Ejlertsen B
doi: 10.1016/S1470-2045(25)00085-3
RECOMMENDED
Breast Cancer
Health-related quality of life in patients with HR+/HER2- early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor: results from the NATALEE trial
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Clin Cancer Res
Fasching PA, Slamon D, Nowecki Z, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Chan A, Chia S, Martín M, Rugo HS, Loi S, Hurvitz S, Untch M, Afenjar K, Fresco R, Danyliv A, Ferrusi I, Li Z, Hortobagyi G
doi: 10.1158/1078-0432.CCR-24-1724
Breast Cancer
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial
Int J Cancer
Beierlein M, Häberle L, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, Wolf C, Kolberg HC, Brucker C, Janni W, Dall P, Schneeweiss A, Marme F, Sütterlin MW, Ruebner M, Theuser AK, Hofmann NM, Böhm S, Almstedt K, Kellner S, Gass P, Lück HJ, Hein A, Schmatloch S, Kalder M, Uleer C, Juhasz-Böss I, Hanf V, Jackisch C, Müller V, Rack B, Belleville E, Wallwiener D, Rody A, Rauh C, Bayer CM, Uhrig S, Huebner H, Goossens C, Brucker SY, Hack CC, Fehm TN, Fasching PA
doi: 10.1002/ijc.70037